{"nctId":"NCT01655069","briefTitle":"A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","startDateStruct":{"date":"2012-10-04","type":"ACTUAL"},"conditions":["Urinary Bladder, Overactive"],"count":148,"armGroups":[{"label":"Children Treated with Placebo in 905-CL-076","type":"EXPERIMENTAL","interventionNames":["Drug: Solifenacin succinate suspension"]},{"label":"Children Treated with Solifenacin in 905-CL-076","type":"EXPERIMENTAL","interventionNames":["Drug: Solifenacin succinate suspension"]},{"label":"Adolescents Treated with Placebo in 905-CL-076","type":"EXPERIMENTAL","interventionNames":["Drug: Solifenacin succinate suspension"]},{"label":"Adolescents Treated with Solifenacin in 905-CL-076","type":"EXPERIMENTAL","interventionNames":["Drug: Solifenacin succinate suspension"]}],"interventions":[{"name":"Solifenacin succinate suspension","otherNames":["YM905","solifenacin succinate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has met the inclusion criteria of study 905-CL-076 and completed study 905-CL-076\n\nExclusion Criteria:\n\n* Subject has failed the exclusion criteria of study 905-CL-076","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With and Severity of Treatment-Emergent Adverse Events (TEAEs)","description":"The investigator assessed the severity of AEs, including abnormal clinical laboratory values, electrocardiogram (ECG), vital signs, as follows:\n\nMild: No disruption of normal daily activities; Moderate: Affect normal daily activities; Severe: Inability to perform daily activities. In participants treated with placebo in Study 905-CL-076, a TEAE was defined as an AE that started/worsened after the first dose of open-label solifenacin in Study 905-CL-077 up to 7 days after the last dose of solifenacin. In participants treated with solifenacin in Study 905-CL-076, a TEAE was defined as an AE that started/worsened after the first dose of double-blind solifenacin in Study 905-CL-076 up to 7 days after last dose of open-label solifenacin in Study 905-CL-077.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours","description":"The mean number of incontinence episodes was based on 7-day diary data completed by participants prior to each visit from the start of 905-CL-076 to the end of 905-CL-077. An Incontinence episode is defined as an episode with any involuntary loss of urine. Data are reported by duration of solifenacin treatment based on the number of days from the date of first dose of solifenacin in either study 905-CL-076 or 905-CL-077 up to and including the study visit. Using equivalent treatment duration periods, data were combined for participants who received placebo and solifenacin in study 905-CL-076 within each age group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.92","spread":"0.18"},{"groupId":"OG001","value":"-1.05","spread":"0.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"0.17"},{"groupId":"OG001","value":"-1.40","spread":"0.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"0.19"},{"groupId":"OG001","value":"-1.48","spread":"0.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.20"},{"groupId":"OG001","value":"-1.66","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.61","spread":"0.19"},{"groupId":"OG001","value":"-1.73","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.66","spread":"0.23"},{"groupId":"OG001","value":"-1.49","spread":"0.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.56","spread":"0.22"},{"groupId":"OG001","value":"-1.34","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Dry (Incontinence-Free) Days Per 7 Days","description":"The number of dry (incontinence-free) days was based on 7-day diary data completed by participants prior to each visit from start of 905-C L-076 to end of 905-C L-077. An incontinence-free day is a day without any incontinence episodes. Data are reported by duration of solifenacin treatment based on the number of days from the date of first dose of solifenacin in either study 905-CL-076 or 905-CL-077 up to and including the study visit. Using equivalent treatment duration periods, data were combined for participants who received placebo and solifenacin in study 905-CL-076 within each age group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"0.16"},{"groupId":"OG001","value":"1.69","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"0.19"},{"groupId":"OG001","value":"2.21","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"0.21"},{"groupId":"OG001","value":"1.94","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"0.21"},{"groupId":"OG001","value":"2.89","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"0.22"},{"groupId":"OG001","value":"3.19","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"0.25"},{"groupId":"OG001","value":"2.71","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.57","spread":"0.40"},{"groupId":"OG001","value":"3.27","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Number of Micturitions Per 24 Hours","description":"The mean number of micturitions (urinations) was based on 7-day diary data completed by participants prior to each visit from start of 905-CL-076 to end of 905-CL-077. Data are reported by duration of solifenacin treatment based on the number of days from the date of first dose of solifenacin in either study 905-CL-076 or 905-CL-077 up to and including the study visit. Using equivalent treatment duration periods, data were combined for participants who received placebo and solifenacin in study 905-CL-076 within each age group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"0.18"},{"groupId":"OG001","value":"-1.29","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"0.20"},{"groupId":"OG001","value":"-1.38","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"0.20"},{"groupId":"OG001","value":"-1.15","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.09","spread":"0.21"},{"groupId":"OG001","value":"-1.24","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.42","spread":"0.21"},{"groupId":"OG001","value":"-1.01","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.43","spread":"0.24"},{"groupId":"OG001","value":"-1.39","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.80","spread":"0.43"},{"groupId":"OG001","value":"-0.81","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Number of Grade 3 or 4 Urgency Episodes Per 24 Hours in Adolescents","description":"Adolescent participants were also asked to record urgencies for at least 2 of the 7 diary days using the Perception of Intensity of Urgency Scale (PPIUS): (0 - no urgency, 1 - mild urgency, 2 - moderate urgency, 3 - severe urgency, 4 - urge incontinence). This data is based on 7-day diary data completed by participants prior to each visit from the start of 905-CL-076 to the end of 905-CL-077. Data are reported by duration of solifenacin treatment based on the number of days from the date of first dose of solifenacin in either study 905-CL-076 or 905-CL-077 up to and including the study visit. Using equivalent treatment duration periods, data were combined for participants who received placebo and solifenacin in study 905-CL-076 within each age group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"0.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.11","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.18","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Final Visit in Postvoid Residual (PVR) Volume","description":"PVR volume was assessed by ultrasonography or bladder scan during 905-CL-076 and 905-CL-077. The value reported is the last PVR volume value after first dose of solifenacin up to 52 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"11.9"},{"groupId":"OG001","value":"0.7","spread":"8.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":118},"commonTop":["Nasopharyngitis","Headache","Constipation","Electrocardiogram QT prolonged","Gastroenteritis"]}}}